ALK and non-small cell lung carcinoma: Great progress has also been made in the use of ALK inhibitors for the treatment of patients with ALK‐positive NSCLC, from crizotinib to second‐generation ALK inhibitors, including alectinib, brigatinib and ensartinib, and lorlatinib, a third‐generation ALK inhibitor [103].